SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of Sept. 8, 2026, a 79% increase from 7,885 at year-end 2025. The company’s installed base also expanded 42% to 238 systems from 168, according to an update on the continued expansion of the platform. This growth underscores the accelerating adoption of robotic surgery worldwide and positions SS Innovations as a key player in the global surgical robotics market.
The SSi Mantra is now installed across 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company’s success in penetrating diverse healthcare markets and expanding access to advanced surgical care.
SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements demonstrate the system’s reliability and efficiency in high-volume settings, which is critical for broader adoption.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal for SS Innovations, as they would open up two of the largest and most lucrative markets for surgical robotics. The FDA clearance and CE marking would significantly enhance the company’s global reach and competitive positioning.
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. To view the full report, visit https://ibn.fm/DJILj.
